Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3

Journal of Infection

Volumn 51, Issue 5, 2005, Pages 355-363

  Jenkins, Stephen G ^a   Farrell, David J ^b   Patel, Manish ^c   Lavin, Bruce S ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b GR Micro Ltd   (United Kingdom)

^c SANOFI   (France)

Author keywords

Erythromycin; Genotype; Levofloxacin; Macrolide; Multidrug resistance; Penicillin; Surveillance; Telithromycin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFUROXIME AXETIL; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; TELITHROMYCIN; TETRACYCLINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CHILD; DILUTION; FEMALE; GENETIC IDENTIFICATION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HUMAN; IN VITRO STUDY; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; KETOLIDES; MACROLIDES; MALE; MEMBRANE PROTEINS; METHYLTRANSFERASES; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 29444450403     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2005.04.015     Document Type: Article

References (29)

1. M.S. Niederman L.A. Mandell A. Anzueto J.B. Bass W.A. Broughton G.D. Campbell et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention Am J Respir Crit Care Med 163 2001 1730-1754
2. P. Ball Epidemiology of chronic bronchitis and its exacerbations Chest 108 Suppl 2 1995 43S-52S
3. J.B. Anon M.R. Jacobs M.D. Poole P.G. Ambrose M.S. Benninger J.A. Hadley et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis Otolaryngol Head Neck Surg 130 Suppl 1 2004 1-45
4. M.A. Pfaller R.N. Jones G.V. Doern K. Kugler Bacterial pathogens isolated from patients with bloodstream infections: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997) Antimicrob Agents Chemother 42 1998 1762-1770
5. D. Felmingham R.N. Grüneberg The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections J Antimicrob Chemother 45 2000 191-203
6. D.J. Hoban G.V. Doern A.C. Fluit M. Roussel-Delvallez R.N. Jones Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999 Clin Infect Dis 31 Suppl 2 2001 S81-S93
7. D. Felmingham R.R. Reinert Y. Hirakata A. Rodloff Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin J Antimicrob Chemother 50 Suppl S1 2002 25-37
8. G.V. Doern M.A. Pfaller K. Kugler J. Freeman R.N. Jones Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program Clin Infect Dis 27 1998 764-770
9. G.V. Doern K.P. Heilmann H.K. Huynh P.R. Rhomberg S.L. Coffman A.B. Brueggemann Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995 Antimicrob Agents Chemother 45 2001 1721-1729
10. D. Hoban K. Waites D. Felmingham Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: Findings of the PROTEKT surveillance study Diagn Microbiol Infect Dis 45 2003 251-259
11. J.A. Karlowsky C. Thornsberry I.A. Critchley M.E. Jones A.T. Evangelista G.J. Noel et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: Results from 2000-2001 and 2001-2002 TRUST studies in the United States Antimicrob Agents Chemother 47 2003 1790-1797
12. G.V. Doern S.D. Brown Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: Data from PROTEKT US 2000-2001 J Infect 48 2004 56-65
13. R. Leclercq P. Couvalin Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification Antimicrob Agents Chemother 35 1991 1267-1272
14. J. Sutcliffe Resistance to macrolides mediated by efflux mechanism Curr Opin Anti-Infect Investig Drugs 1 1999 403-412
15. D.J. Farrell I. Morrissey S. Bakker D. Felmingham Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study J Antimicrob Chemother 50 Suppl 1 2002 39-47
16. A. Corso E.P. Severina V.F. Petruk Y.R. Mauriz A. Tomasz Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States Microb Drug Resist 4 1998 325-337
17. D.J. Farrell S.G. Jenkins Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002 J Antimicrob Chemother 54 Suppl 1 2004 I17-I22
18. D.J. Farrell I. Morrissey S. Bakker L. Morris S. Buckridge D. Felmingham Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance J Clin Microbiol 42 2004 764-768
19. D.J. Farrell I. Morrissey S. Bakker S. Buckridge D. Felmingham In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations Antimicrob Agents Chemother 48 2004 3169-3171
20. K. Waites S. Brown Antimicrobial resistance among isolates of respiratory tract infection pathogens from the Southern United States: data from the PROTEKT US surveillance program 2000/2001 South Med J 96 2003 974-985
21. D. Felmingham The need for antimicrobial resistance surveillance J Antimicrob Chemother 50 Suppl 1 2002 1-7
22. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A6. Wayne, PA: CLSI; 2003.
23. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; 15th Informational Supplement. Document M100-S15 2005 CLSI Wayne, PA
24. D.J. Farrell I. Morrissey S. Bakker D. Felmingham Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization J Antimicrob Chemother 48 2001 541-544
25. J. Shackcloth L. Williams D.J. Farrell Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: The in vitro activity of telithromycin versus comparators J Infect 48 2004 229-235
26. M.A. Kelley D.J. Weber P. Gilligan M.S. Cohen Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin Clin Infect Dis 31 2000 1008-1011
27. J.R. Lonks What is the clinical impact of macrolide resistance? Curr Infect Dis Rep 6 2004 7-12
28. D.J. Farrell D. Felmingham Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003 Antimicrob Agents Chemother 48 2004 1882-1884
29. R. Reinert D. Felmingham The EU PROTEKT Study Group High sustained activity of telithromycin post-launch in Europe: The PROTEKT study (years 1-4) [abstract C2-813] 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30-November 2 2004